Last reviewed · How we verify

FLUTRIMAZOLE — Competitive Intelligence Brief

FLUTRIMAZOLE (FLUTRIMAZOLE) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: flutrimazole. Area: Metabolic.

phase 2 flutrimazole Nuclear receptor subfamily 1 group I member 2, Bile acid receptor Metabolic Small molecule Live · refreshed every 30 min

Target snapshot

FLUTRIMAZOLE (FLUTRIMAZOLE). Flutrimazole works by binding to and activating the nuclear receptor subfamily 1 group I member 2, which plays a role in regulating gene expression.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
FLUTRIMAZOLE TARGET FLUTRIMAZOLE phase 2 flutrimazole Nuclear receptor subfamily 1 group I member 2, Bile acid receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (flutrimazole class)

  1. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). FLUTRIMAZOLE — Competitive Intelligence Brief. https://druglandscape.com/ci/flutrimazole. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing